How does Johnson & Johnson's COVID-19 vaccine stack up against shots from Pfizer and Moderna?
Covid-19 vaccine Pfizer-BioNTech vials.
Patrick Fallon and AFP via Getty Images
Vaccine COVID-19 from Johnson & Johnson showed 66% effective in the prevention of mild and moderate infections and 85% efficient in the prevention of serious infections in Wednesday's FDA results.
It appears not as effective as Moderna or Pfizer's mRNA vaccines, but it is just as effective in avoiding hospitalization and death.
It has the advantages of being inexpensive and easy to produce and sell.
It just takes one shot in the arm with milder side effects.
Visit the homepage of Business Insider for more articles.
According to new US Food and Drug Administration data released on Wednesday, the Johnson & Johnson experimental coronavirus vaccine is 66 percent successful in prevention of mild to serious COVID-19.
At first sight, the vaccine is not as stellar as the FDA-approved Pfizer and Moderna vaccines but has a few benefits.
The vaccine of J&J is just one shot in the arm, and both Pfizer and Moderna are administered in two doses, given several weeks apart.
Second, it can be cooled for three months, which makes transport and storing much less difficult.
Third, a milder range of side effects emerges.
And ultimately, the production is quicker and faster.
"Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic," said Alex Gorsky, Chief Executive Officer of Johnson & Johnson in the statement when the company's results were reported at the end of January.
Dr. Anthony Fauci, US leading infectious disease specialist, also stressed last month during a call at the National Institutes of Health to bring "yet another platform, another candidate into the mix in our global efforts against this extraordinary pandemic."
"This has really important domestic and global public health implications," said Fauci on the J&J vaccine, adding that "it is one shot," The results do not have to be stored at super-chilled temperatures and are comparatively inexpensive.
The J&J shot is being checked by the FDA and may be approved to be used in the United States earlier this weekend.
Here are the fundamentals of how these three shots equate COVID-19 depending on what we observe.
How well does shooting deter disease:
Modern: 94,1% effective in symptomatic infection control, 100% effective in the prevention of serious infections after two doses.
Pfizer: 95% effective in prevention of symptomatic infections; almost 100% effective for prevention of serious infections (one case of over 18,000 vaccinated people), after two doses.
Johnson & Johnson: 66% effective to avoid mild to serious infections; 85% effective to prevent serious infections after a single dosage.
(Five of the more than 19,000 fully vaccinated individuals who had received the shot at least 28 days earlier were reported serious cases.)
Bruno Cassaro de Andrade, a student in chemistry engineering, is working on a research separating special proteins to be used in the manufacture of coronavirus vaccines in Belo Horizonte, Brazil, on March 24, 2020.
Pedro Villa/Getty Images
How well did the fire avert hospitalization and death:
Modern: Zero or deaths 14 days after the second shot.
Pfizer: zero hospitalizations or deaths following the second fired seven days after.
Johnson & Johnson: Zero or death 28 days after a single shot.
How many people have tried it:
Modern: more than 30,000 volunteers in the US were interested in trials.
Pfizer: experiments have included more than 40,000 participants in six continents, including the United States, Argentina, Brazil, Turkey, Germany and South Africa.
Johnson & Johnson: over 40,000 participants were tested in eight countries: the USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa.
Roughly half of the volunteers in each company's sample received actual shots and half received (placebo) artificial jabs to test the vaccinations as well as none.
How they work: How they work
Modern: mrna. modern.
Adenovirus Johnson & Johnson: Adenovirus.
(It is the same forum as the European Union authorised Ebola vaccine last July.)
Where to take them: How to take them?
Modern: Two shots in the shoulder, separated by 28 days.
Pfizer: Two arm blasts, 21 days apart.
Johnson & Johnson: One arm blast.
A nurse at Royal Cornwall Hospital is planning to deliver a vaccine COVID-19 in Truro, UK.
Hugh Hasting/Getty Images
Most important adverse events:
Modern: pain in the arm (91.6%), exhaustion (68.5%), headache (63.0%), body pain (59.6%), joint suffering (44.5%) and chills (43.4 percent ).
Pfizer: pain in the arm (84.1%), exhaustion (62.9%), headache (55.1%), muscular pain (38.3%), frolics (31.9%), knee pain (23.6%), fever (14.2 percent ).
Johnson & Johnson: shoulder pain (48.6%), headaches (38.9%), tiredness (38.2%) and body aches (33.2 percent ).
How long safety takes to get started:
Modern: certain infection defense starts 10-14 days after the first shot with complete protection two weeks after the second shot.
Pfizer: certain infection protection starts 10-14 days after the first shot with maximum protection attained one week after the second.
Johnson & Johnson: some infection protection starts 14 days after the shot, with maximum protection 28 days after the shot.
How long hospitals and clinics should keep it in the refrigerator
New: 30 days. Modern.
Pfizer: five days. Five days.
Johnson & Johnson: Three months, three months.
New material from the FDA briefing papers has been revised for this article.
Read the original Business Insider post